227. Osler disease Clinical trials / Disease details


Clinical trials : 54 Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-003982-24-ES
(EUCTR)
16/03/201709/12/2016Study to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeksA phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeks Hereditary hemorrhagic telangiectasia
MedDRA version: 19.0;Level: LLT;Classification code 10020023;Term: HHT;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Dicynone
INN or Proposed INN: Etamsylate
Other descriptive name: ETAMSYLATE
Asociación HHT EspañaNULLNot Recruiting Female: yes
Male: yes
12 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesSpain